eDreams ODIGEO's Deep Dive: Key Takeaways

Presented by CFO David Elizaga

eDreams ODIGEO is entering what management describes as a decisive inflection point in its corporate development. In this deep dive, David Elizaga, Chief Financial Officer, outlines why the company’s recent strategic shift represents not a defensive adjustment but a high-conviction move designed to unlock a significantly larger addressable market and a more predictable earnings profile over the long term.

A Strategic Reset Focused on Long-Term Value Creation

Management begins by directly addressing the sharp share price correction of roughly 60 percent following the November 2025 strategy update. The market reaction was driven primarily by the decision to introduce a monthly payment option for Prime subscriptions alongside the existing annual model.

This change results in a one-time cash unwind in the short term, temporarily depressing reported Cash EBITDA and free cash flow in FY26 and FY27. Crucially, CFO David Elizaga stresses that this is a timing effect rather than a loss of value. The cash is still contractually secured but received over twelve months instead of upfront.

In essence, eDreams is deliberately trading near-term cash acceleration for structurally higher market penetration, faster subscriber growth, and a more diversified revenue base.

Why the Monthly Model Is a Growth Catalyst

The introduction of monthly Prime subscriptions materially lowers the entry barrier for customers and significantly expands the total addressable market. Management now targets more than 13 million Prime members and over €270 million in Cash EBITDA by FY30.

Beyond scale, the business mix improves meaningfully. The Prime platform becomes less dependent on European flights and increasingly diversified across geographies and travel products. By FY30, more than two thirds of volumes are expected to be generated outside the traditional European flight segment.

Importantly, this transition is not theoretical. eDreams has already demonstrated its ability to scale Prime from roughly two million to over seven million members, giving management strong confidence in execution.

Track Record of Delivering on Long-Term Plans

A central pillar of the investment case is credibility. Since David Elizaga became CFO, eDreams has executed three long-term strategic plans, each time delivering on the guidance provided.

The current strategy is framed as a continuation of this disciplined approach. Management highlights that the 2021 strategic plan involved significantly higher risk and was delivered successfully despite severe external shocks including the pandemic aftermath, geopolitical conflicts, inflation, and weak consumer sentiment.

Against this backdrop, the CFO argues that the current valuation reaction does not reflect execution reality.

Valuation Disconnect and Market Assumptions

Management identifies a pronounced disconnect between internal expectations and sell-side valuation frameworks. Analysts are currently applying conservative assumptions across multiple dimensions....

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

T&C

This publication is intended solely for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions as outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Presented by CFO Michael Schneiders

Brain Biotech AG has concluded the 2024/25 financial year with a clear strategic signal to capital markets: the company is increasingly translating its technology platform into tangible financial results through disciplined monetization, operational focus, and strict cost control.

In the FY 2024/25 results presentation, Michael Schneiders, Chief Financial Officer, outlines how Brain Biotech is progressing from a technology-driven innovation platform toward a more cash-generative, scalable industrial biotechnology group.

Strategic Focus: From Innovation to Monetization

The 2024/25 financial year marked an important transition phase for Brain Biotech. Management placed a strong emphasis on monetizing selected assets and projects while maintaining technological leadership in enzyme innovation and industrial biotechnology.

Rather than pursuing broad expansion, the company focused on converting prior R&D investments into measurable economic outcomes. This included milestone payments, licensing income, and structured partnerships, particularly within the enzyme and biocatalysis segments. These initiatives underline Brain Biotech’s ability to extract value from its technology portfolio without diluting strategic optionality.

Cost Discipline and Margin Stabilization

A defining feature of FY 2024/25 was the company’s strict cost discipline. Brain Biotech implemented targeted efficiency measures across the organization, prioritizing high-value activities while reducing structural overhead.

This disciplined approach helped stabilize margins despite a challenging macroeconomic environment for biotechnology and life sciences companies. Management made clear that profitability and cash preservation are now core steering metrics, reinforcing investor confidence in Brain Biotech’s financial governance.

Core Segment: Enzyme and Industrial Biotechnology Growth

The enzyme business remains the operational backbone of Brain Biotech. The company continues to benefit from long-term structural demand for sustainable, energy-efficient, and biodegradable solutions across food, life sciences, and industrial applications.

Brain Biotech’s integrated platform—combining biodiversity libraries, AI-supported enzyme discovery, and proprietary strain engineering—provides a competitive advantage in addressing customer-specific applications. Importantly, the company is increasingly shifting toward higher-margin, proprietary enzyme products rather than purely project-based revenues.

AI as a Competitive Accelerator

Artificial intelligence plays a growing role in Brain Biotech’s operating model. Management emphasized that AI is not a standalone strategy but a productivity and speed enhancer across enzyme discovery, optimization, and commercialization.

By integrating AI-driven tools into its R&D and development processes, Brain Biotech shortens time-to-market, improves success rates, and strengthens customer value propositions—an increasingly relevant differentiator in industrial biotechnology.

Financial Position and Capital Allocation

From a balance sheet perspective, Brain Biotech remains focused on financial resilience. Cash management, selective capital allocation, and disciplined investment decisions underpin the group’s medium-term strategy.

Management reiterated that future growth will be driven primarily by organic expansion in the enzyme segment, complemented by selective monetization of non-core or mature assets. M&A remains opportunistic rather than mandatory, ensuring financial flexibility in volatile markets... ..

T&C

This publication is intended solely for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions as outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Carl Zeiss Meditec AG FY 2024/25: Key Takeaways

Carl Zeiss Meditec FY 2024/25 Financial Results

Strategic Realignment Drives Resilient Growth and Sets the Stage for Margin Expansion

In its FY 2024/25 financial results presentation, Carl Zeiss Meditec Group demonstrates that it remains firmly positioned in structurally attractive global healthcare technology markets, while simultaneously acknowledging the need for sharper execution and strategic focus to unlock its full earnings potential. The year was marked by solid revenue growth, robust order intake, and the first tangible effects of a broader strategic realignment aimed at restoring profitability momentum over the medium term.

Solid Top-Line Growth and Strong Order Momentum

Carl Zeiss Meditec delivered reported revenue of approximately €2.23 billion in FY 2024/25, reflecting solid growth compared with the prior year. On a foreign-exchange adjusted basis, revenue growth was clearly positive, supported by a combination of organic demand and the full-year consolidation of DORC in Ophthalmology. Order intake developed particularly strongly, increasing at a double-digit rate year-on-year on a constant-currency basis, resulting in a healthy order backlog that underpins revenue visibility into the new fiscal year.

Growth was broad-based across regions. EMEA and the Americas showed especially strong momentum, while Asia-Pacific continued to contribute meaningfully despite a more challenging environment in China. Importantly for investors, order entry growth outpaced revenue growth, signalling ongoing demand strength across key product categories and geographies.

Earnings: Stable EBITA Amid Headwinds, Adjusted Margin Improvement

On the profitability side, EBITA increased slightly year-on-year, landing broadly in line with management guidance. Reported EBITA margin declined modestly compared with the prior year, reflecting a combination of adverse foreign exchange effects, US tariff-related headwinds, and a prior-year one-off gain related to the Topcon settlement. On an adjusted basis, however, EBITA margin improved, underlining the underlying progress in operating efficiency.

A key positive driver was the reduction in underlying operating expenses excluding DORC effects, particularly through lower R&D spending and reduced integration costs. This demonstrates early discipline in capital allocation and cost management, even as the company continues to invest selectively in future growth areas.

Segment Performance: Ophthalmology Strengths Offsets Microsurgery Transition

Ophthalmology remained the group’s core earnings pillar. Consumables, premium intraocular lenses, and the full-year contribution from DORC drove revenue growth in this segment. Margin expansion in Ophthalmology was supported by operating leverage and improved cost discipline, reinforcing the segment’s role as the primary value driver within the portfolio.

Microsurgery, while showing a recovery in revenue momentum toward year-end, continued to face margin pressure due to product mix effects, delayed ramp-up of new systems, and ongoing investments in commercialization and market development. Management clearly positioned this as a transitional phase, with expectations of improved profitability as new products scale and operational measures take effect.

....

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

T&C

This publication is intended solely for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions as outlined on www.seat11a.com/legal and www.seat11a.com/imprint.